FEATURE SELECTION APPLIED TO MICROBIOME FOR DRUG DISCOVERY

David Rojas-Velazquez, Sarah Kidwai, Lara Cerezin, Luciënne de Vries, Kosta Besermenji, Paula Perez-Pardo, Alejandro Lopez-Rincon

HAL Id: hal-04097608
https://hal.science/hal-04097608

Submitted on 15 May 2023

FEATURE SELECTION APPLIED TO MICROBIOME FOR DRUG DISCOVERY

David Rojas-Velazquez (1,2), Sarah Kidwai (1), Lara Cerezin(1), Luciënne de Vries(1), Kosta Besermenji(1), Paula Perez-Pardo(1), Alejandro Lopez-Rincon (1,2)
1. Utrecht University, Pharmacology, Netherlands; 2. Julius Center UMC Utrecht, Netherlands

1. Introduction

Inflammatory bowel disease (IBD) is a term that describes conditions characterized by chronic inflammation of the gastrointestinal (GI) tract caused by various factors: abnormal gut microbiota, immune response dysregulation, environmental changes and gene variants. There are two types of IBD: Crohn's disease (CD) and ulcerative colitis (UC). Currently, there is no treatment for IBD, but it can be managed by using aminosalicylates, immunosuppressants or biologics[1].

2. Materials and Methods

The data used is from *Alam et al* [1], where fecal samples were collected from 30 individuals (20 IBD and 10 healthy volunteers) with 16S rRNA taxonomic profiling. Raw data was analysed using the DADA2 pipeline [2] and the Recursive Ensemble Feature Selection (REFS), and we compared with the original results. REFS is a method to discover biomarkers, the ensemble for the feature selection phase is composed by 8 classifiers from the sci-kit learn toolbox [3]: Stochastic Gradient Descent, Support Vector Machine classifier, gradient boosting, random forest, logistic regression, passive aggressive classifier, ridge classifier and bagging [4,5]. Once the features were selected, are validated using 5 different classifiers from the sci-kit learn toolbox [3] not part from the ensemble.

3. Results

REFS selected 5 sequences (features) from the original 3226, with an AUC of 0.92, considered as excellent in medical diagnostics [6]. The resulting taxa are 5 out 3 at genus level: *Lactobacillus* (F1), *UCG-002* (F2) and *Fusicatenibacter* (F5), and 2 *Lachnospirales* that will require more study in tools such as BLAST[2].

4. Discussion and Conclusions

As shown inFigure 2, the use of ML with REFS give us better results and closer to reality. E.g. the first feature selected was genus lactobacillus

Figure 1: 10 runs of the REFS algorithm, with best answer at 5 taxa (vertical red line).


Figure 2: ROC Comparison between the original results from [1] (left) and the results using REFS (right).

and it was shown to be underexpressed in IBD patients. Lactobacillus is a component of lactic acid bacteria, a bacteria group described by the formation of lactic acid as a main end product of carbohydrate metabolism [7]. Lactobacilli are a major part of the commensal microbial flora of small and large intestine in humans and animals, and are often used as probiotics [8]. An overview in [9] described the use of VSL #3 which consists of 8 bacterial strains, 4 of those are Lactobacillus strains. It has been shown that VSL #3 was able to induce a significant increase in protective bacterial strains and can induce remission in patients with mild to moderate UC [9], this could be a first step towards a treatment.

5. References

1. Alam MT et al., Gut pathogens. 2020;12(1):1-8 (2020).
2. Callahan B et al., Nature methods. 2016;13(7):581-583 (2016).
3. Pedregosa F et al., The Journal of machine Learning research. 2011;12:2825-2830 (2011).
4. Lopez-Rincon A et al., BMC bioinformatics. 2019;20(1):1-17 (2019).
5. Lopez-Rincon A et al., BMC bioinformatics. 2020;12(7):785 (2020).
6. Šimundić AM, ejifcc. 2009;19(4):203 (2009).
7. Tannock GW, Applied and Environmental Microbiology. 2004;70(6):3189–94 (2004).
8. Christensen HR, The Journal of Immunology. 2002;168(1):171–8 (2002).
9. Cheng FS, World Journal of Clinical Cases. 2020; 8(8):1361–84 (2020).

[1] https://www.nhs.uk/conditions/inflammatory-bowel-disease/

[2] https://blast.ncbi.nlm.nih.gov/Blast.cgi